3 hours Eli Lilly’s Breakout Is Nearly Here: Performance Metrics/Bullish Support Remain Robust Seeking Alpha X
2 days New weight-loss drugs like Mounjaro are hot right now. Eli Lilly’s CEO explains why they’re so expensive. Business Insider X
1 week Think Eli Lilly’s Stock Is Expensive? Here’s Why Selling It Now Could Be a Huge Mistake Yahoo Finance X
2 weeks Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 Yahoo Finance X
2 weeks Eli Lilly Jumps, Reversing Its Weight-Loss Setback, On A Strong 2025 Outlook Investor's Business Daily X
3 weeks The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb Zacks X
3 weeks Eli Lilly CEO Hasn’t Bought Company Shares in Years. He Just Bought This Stock. Yahoo Finance X
4 weeks Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It. Yahoo Finance X
4 weeks Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho’s Jared Holz YouTube X
1 month Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk Investor's Business Daily X
1 month Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity? Yahoo Finance X
1 month After Eli Lilly’s 7% Slump On Its Guidance Cut, What’s Left To Like? A Lot, Says One Analyst. Investor's Business Daily X
1 month Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today. Yahoo Finance X
Stock Market News